The Learning Edge
metadata only
Supporting adherence to adjuvant CDK4/6 inhibitors in women with early breast cancer (SWEET-PLUS) : protocol for a multicentre UK study using qualitative and co-development methods
Introduction. Breast cancer is the most common cancer in women in the UK. For women who have early-stage oestrogen-receptor positive (ER+ve) disease, daily oral adjuvant endocrine therapy reduces risk of recurrence. Recently, CDK4/6 inhibitors, a form of biological therapy, have been approved for us
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer#849528
- Experience of the Patient Treated With Trastuzumab (Herceptin ®) as Adjuvant for Breast Cancer#1088622
- Trial of Perioperative Endocrine Therapy - Individualising Care#1033621
- Breast Cancer RElapsed in Patients Treated With Adjuvant CDK4/6 Inhibitors:#1151223
- A Randomized Controlled Trial (RCT) to Determine the Efficacy of a Multidisciplinary CBT Based Pain Management Program for the Treatment of Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS) in Breast Cancer Survivors#1031417
Record · ID 990111
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive